Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial

Alberto Martini(The University of Texas MD Anderson Cancer Center), William Oh(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), John Pfail(Icahn School of Medicine at Mount Sinai), Francesco Montorsi(Vita-Salute San Raffaele University)
Prostate Cancer and Prostatic Diseases
April 20, 2020
10.1038/s41391-020-0231-5
Cited by 13

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Whole-Body Hypothermia for Neonates with Hypoxic–Ischemic Encephalopathy
|New England Journal of Medicine|2005|2.8k
Late-Onset Sepsis in Very Low Birth Weight Neonates: The Experience of the NICHD Neonatal Research Network
|PEDIATRICS|2002|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k